Similarly, miRNAs profiling could also be used to monitor response to IFN‐β therapy, since treated RR‐MS patients showed up‐regulation in the serum of 2 miRNAs (e.g., miR‐22‐3p and miR‐660‐5p), compared to the untreated group.72 Here, IFNB1 is linked to myeloid sarcoma.